European Journal of Medicinal Chemistry 2010-10-01

Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.

Chatchawan Changtam, Poonpilas Hongmanee, Apichart Suksamrarn

Index: Eur. J. Med. Chem. 45 , 4446-57, (2010)

Full Text: HTML

Abstract

Curcumin (1), demethoxycurcumin (2) and bisdemethoxycurcumin (3), the curcuminoid constituents of the medicinal plant Curcuma longa L., have been structurally modified to 55 analogs and antimycobacterial activity against Mycobacterium tuberculosis has been evaluated. Among the highly active curcuminoids, the isoxazole analogs are the most active group, with mono-O-methylcurcumin isoxazole (53) being the most active compound (MIC 0.09 microg/mL). It was 1131-fold more active than curcumin (1), the parent compound, and was approximately 18 and 2-fold more active than the standard drugs kanamycin and isoniazid, respectively. Compound 53 also exhibited high activity against the multidrug-resistant M. tuberculosis clinical isolates, with the MICs of 0.195-3.125 microg/mL. The structural requirements for a curcuminoid analog to exhibit antimycobacterial activity are the presence of an isoxazole ring and two unsaturated bonds on the heptyl chain. The presence of a suitable para-alkoxyl group on the aromatic ring which is attached in close proximity to the nitrogen function of the isoxazole ring and a free para-hydroxyl group on another aromatic ring enhances the biological activity.Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.


Related Compounds

Related Articles:

Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.

2014-12-01

[Tuberculosis (Edinb.) 94(6) , 701-7, (2015)]

Disruption of an M. tuberculosis membrane protein causes a magnesium-dependent cell division defect and failure to persist in mice.

2015-02-01

[PLoS Pathog. 11(2) , e1004645, (2015)]

Kinetics of recA and recX induction in drug-susceptible and MDR clinical strains of Mycobacterium tuberculosis.

2014-12-01

[J. Antimicrob. Chemother. 69(12) , 3199-202, (2014)]

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.

2014-01-01

[PLoS ONE 9(4) , e93953, (2014)]

Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.

2015-02-01

[Pulm. Pharmacol. Ther. 30 , 80-6, (2015)]

More Articles...